Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First insights and future research perspectives from the sarcoidosis registry at the Medical University of Vienna.

Scientific reports·2025
Same author

Corrigendum to "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications".

BioMed research international·2023
Same author

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.

BioMed research international·2021
Same author

Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria.

Frontiers in pharmacology·2021
Same author

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.

Expert review of pharmacoeconomics & outcomes research·2021
Same author

Calculated initial parenteral treatment of bacterial infections: Bacterial endocarditis.

GMS infectious diseases·2020

Related Experiment Video

Updated: Jul 10, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Daptomycin: a review 4 years after first approval.

Robert Sauermann1, Markus Rothenburger, Wolfgang Graninger

  • 1Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Vienna, Austria.

Pharmacology
|October 18, 2007
PubMed
Summary

Daptomycin, a cyclic lipopeptide antibiotic, effectively treats Gram-positive infections by disrupting bacterial cell membranes. Its concentration-dependent action and favorable safety profile support its use, with potential for higher doses in severe cases.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Experiment Videos

Last Updated: Jul 10, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Daptomycin is a novel cyclic lipopeptide antibiotic.
  • It exhibits rapid bactericidal activity against Gram-positive pathogens.
  • Its mechanism involves bacterial cell membrane disruption, leading to pore formation and inhibition of essential synthesis.

Purpose of the Study:

  • To review the history, mechanism of action, and clinical applications of daptomycin.
  • To discuss daptomycin's susceptibility patterns, including against multidrug-resistant strains.
  • To evaluate daptomycin's efficacy and safety in treating various Gram-positive infections.

Main Methods:

  • Review of existing literature on daptomycin's pharmacology and clinical studies.
  • Analysis of pharmacokinetic/pharmacodynamic (PK/PD) data, focusing on Cmax/MIC and AUC/MIC ratios.
  • Examination of susceptibility data from large international studies.

Main Results:

  • Daptomycin's efficacy is concentration-dependent, correlating with Cmax/MIC and AUC/MIC ratios.
  • Intravenous daily administration is recommended to minimize myopathy risk.
  • Daptomycin is non-inferior to standard therapies for complicated skin infections and S. aureus bacteremia.

Conclusions:

  • Daptomycin is a valuable treatment option for Gram-positive infections, including resistant strains.
  • Optimized dosing regimens, potentially higher than currently approved, may be beneficial for severe infections.
  • Caution is advised with daptomycin use following vancomycin therapy due to potential cross-resistance.